Dr. Morgan has spent his career overseeing research programs focused on engineered cell medicines and gene therapies, including the development and advancement of multiple oncology medicines. He served as Vice President Immunotherapy, bluebird bio from 2013 – 2018. While at bluebird bio, Dr. Morgan’s team developed the company’s lead oncology asset bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma. Prior to his position at bluebird bio, Dr. Morgan was a Staff Scientist for the Surgery Branch of the National Cancer Institute and the Interim Chief of the Clinical Gene Therapy Branch of the National Human Genome Research Institute. Dr. Morgan is a member of the board of directors of the American Society of Gene and Cell Therapy (ASGCT), serving as the translational and clinical development representative, and he has published more than 150 scientific papers during his career. He received his Ph.D. in genetics from John Hopkins University and his B.A. in biochemistry from Brandeis University.